PL406033A1 - Sposób diagnozowania raka brodawkowatego tarczycy, zastosowanie markera mikroRNA do diagnozowania nowotworu tarczycy, oceny stopnia zaawansowania choroby oraz oceny podatności pacjenta i/lub choroby na zaproponowane leczenie oraz zawierający takie markery zestaw diagnostyczny - Google Patents

Sposób diagnozowania raka brodawkowatego tarczycy, zastosowanie markera mikroRNA do diagnozowania nowotworu tarczycy, oceny stopnia zaawansowania choroby oraz oceny podatności pacjenta i/lub choroby na zaproponowane leczenie oraz zawierający takie markery zestaw diagnostyczny

Info

Publication number
PL406033A1
PL406033A1 PL406033A PL40603313A PL406033A1 PL 406033 A1 PL406033 A1 PL 406033A1 PL 406033 A PL406033 A PL 406033A PL 40603313 A PL40603313 A PL 40603313A PL 406033 A1 PL406033 A1 PL 406033A1
Authority
PL
Poland
Prior art keywords
diagnosing
thyroid
carcinoma
mir
patient
Prior art date
Application number
PL406033A
Other languages
English (en)
Inventor
Krystian Jażdżewski
Anna Wójcicka
Anna Kubiak
Wojciech Gierlikowski
Monika Maciąg
Monika Kolanowska
Agnieszka Czajka
Marta Kotlarek
Michał Świerniak
Original Assignee
Warszawski Uniwersytet Medyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warszawski Uniwersytet Medyczny filed Critical Warszawski Uniwersytet Medyczny
Priority to PL406033A priority Critical patent/PL406033A1/pl
Priority to PCT/IB2014/066057 priority patent/WO2015071876A2/en
Publication of PL406033A1 publication Critical patent/PL406033A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Przedmiotem wynalazku jest sposób diagnozowania zmiany chorobowej, takiej jak nowotwór i/lub zmiana łagodna tarczycy u pacjenta, który to sposób obejmuje: - dostarczanie pochodzącej od pacjenta próbki biologicznej, - określanie ilości jednego lub więcej mikroRNA wybranego z grupy obejmującej miR-146b-5p, miR-146b-3p, miR-221-5p, miR-221-3p, miR-222-5p, miR-222-3p, miR-181a-5p i miR-182-5p w próbce biologicznej, - porównywanie ekspresji mikroRNA z poziomem ekspresji mikroRNA w grupie kontrolnej, - diagnozowanie wystąpienia nowotworu /i/lub zmiany łagodnej u pacjenta, jeśli poziom ekspresji mikroRNA w próbce biologicznej jest zmieniony względem poziomu ekspresji obserwowanej w próbkach płynów biologicznych w grupie kontrolnej. Przedmiotem wynalazku jest także zastosowanie markera mikroRNA do diagnozowania zmiany chorobowej w obrębie tarczycy oraz zestaw do diagnozowania zmiany chorobowej.
PL406033A 2013-11-14 2013-11-14 Sposób diagnozowania raka brodawkowatego tarczycy, zastosowanie markera mikroRNA do diagnozowania nowotworu tarczycy, oceny stopnia zaawansowania choroby oraz oceny podatności pacjenta i/lub choroby na zaproponowane leczenie oraz zawierający takie markery zestaw diagnostyczny PL406033A1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL406033A PL406033A1 (pl) 2013-11-14 2013-11-14 Sposób diagnozowania raka brodawkowatego tarczycy, zastosowanie markera mikroRNA do diagnozowania nowotworu tarczycy, oceny stopnia zaawansowania choroby oraz oceny podatności pacjenta i/lub choroby na zaproponowane leczenie oraz zawierający takie markery zestaw diagnostyczny
PCT/IB2014/066057 WO2015071876A2 (en) 2013-11-14 2014-11-14 Use of microrna markers for diagnosis of thyroid tumors and a diagnostic panel containing such markers.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL406033A PL406033A1 (pl) 2013-11-14 2013-11-14 Sposób diagnozowania raka brodawkowatego tarczycy, zastosowanie markera mikroRNA do diagnozowania nowotworu tarczycy, oceny stopnia zaawansowania choroby oraz oceny podatności pacjenta i/lub choroby na zaproponowane leczenie oraz zawierający takie markery zestaw diagnostyczny

Publications (1)

Publication Number Publication Date
PL406033A1 true PL406033A1 (pl) 2015-05-25

Family

ID=53058217

Family Applications (1)

Application Number Title Priority Date Filing Date
PL406033A PL406033A1 (pl) 2013-11-14 2013-11-14 Sposób diagnozowania raka brodawkowatego tarczycy, zastosowanie markera mikroRNA do diagnozowania nowotworu tarczycy, oceny stopnia zaawansowania choroby oraz oceny podatności pacjenta i/lub choroby na zaproponowane leczenie oraz zawierający takie markery zestaw diagnostyczny

Country Status (2)

Country Link
PL (1) PL406033A1 (pl)
WO (1) WO2015071876A2 (pl)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4303323A1 (en) 2022-07-05 2024-01-10 Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Oddzial w Gliwicach A method differentiating benign and malignant tyroid nodules

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
EP2806054A1 (en) 2008-05-28 2014-11-26 Genomedx Biosciences Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
EP3360978A3 (en) 2009-05-07 2018-09-26 Veracyte, Inc. Methods for diagnosis of thyroid conditions
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
WO2013090620A1 (en) 2011-12-13 2013-06-20 Genomedx Biosciences, Inc. Cancer diagnostics using non-coding transcripts
ES2945036T3 (es) 2012-08-16 2023-06-28 Veracyte Sd Inc Pronóstico del cáncer de próstata mediante biomarcadores
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
US20170335396A1 (en) 2014-11-05 2017-11-23 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
AU2017315425B2 (en) 2016-08-24 2023-11-09 The Regents Of The University Of Michigan Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
EP3571322B9 (en) 2017-01-20 2023-10-04 VERACYTE SD, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
CA3055925A1 (en) 2017-03-09 2018-09-13 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
US11078542B2 (en) 2017-05-12 2021-08-03 Decipher Biosciences, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
US12497660B2 (en) 2017-08-04 2025-12-16 Veracyte SD, Inc. Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy
KR102649965B1 (ko) * 2019-01-11 2024-03-22 연세대학교 산학협력단 갑상선 수질암 표적용 조성물
RU2705110C1 (ru) * 2019-04-10 2019-11-06 Государственное бюджетное учреждение здравоохранения "Краевая клиническая больница N2" Министерства здравоохранения Краснодарского края Способ дифференциальной диагностики новообразований щитовидной железы
CN111286538B (zh) * 2020-02-13 2023-04-07 朱伟 一种与泛肿瘤辅助诊断相关的循环miRNA和癌胚miRNA标志物及其应用
CN114196759B (zh) * 2021-12-31 2023-10-20 深圳市海普洛斯生物科技有限公司 一种尿液样本的胰腺癌生物标志物及其应用
CN116769922B (zh) * 2023-08-24 2023-11-24 四川大学华西医院 检测循环sEV RNA试剂的用途、试剂盒和诊断系统
CN118326047A (zh) * 2024-06-14 2024-07-12 润安医学科技(苏州)有限公司 一组microRNA标志物在甲状腺结节良恶性鉴别中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214203A1 (en) 2002-12-12 2004-10-28 Oncotech, Inc. Genes related to sensitivity and resistance to chemotherapeutic drug treatment
US20060160114A1 (en) 2004-12-02 2006-07-20 Oncotech, Inc. Reagents and methods for predicting drug resistance
ES2429404T3 (es) 2006-01-05 2013-11-14 The Ohio State University Research Foundation Procedimientos basados en los microARN para el diagnóstico y el pronóstico del cáncer de pulmón
US20080076674A1 (en) 2006-07-06 2008-03-27 Thomas Litman Novel oligonucleotide compositions and probe sequences useful for detection and analysis of non coding RNAs associated with cancer
EP2090665A2 (en) 2006-10-20 2009-08-19 Exiqon A/S Novel human microRNAs associated with cancer
WO2008154098A2 (en) 2007-06-07 2008-12-18 Wisconsin Alumni Research Foundation Reagents and methods for mirna expression analysis and identification of cancer biomarkers
CA2676113C (en) 2007-07-25 2014-07-08 University Of Louisville Research Foundation, Inc. Exosome-associated microrna as a diagnostic marker
WO2009080437A1 (en) 2007-12-21 2009-07-02 Exiqon A/S Micro-rna based drug resistance analysis method
WO2009143379A2 (en) 2008-05-21 2009-11-26 Fred Hutchinson Cancer Research Center Use of extracellular rna to measure disease
CA2765870A1 (en) 2009-06-19 2010-12-23 Leroi V. Desouza Renal cell carcinoma biomarkers
EP2341145A1 (en) 2009-12-30 2011-07-06 febit holding GmbH miRNA fingerprint in the diagnosis of diseases
WO2012009499A2 (en) 2010-07-15 2012-01-19 Mayo Foundation For Medical Education And Research Assessing thyroid neoplasms and treating cancer
ES2629890T3 (es) * 2010-11-17 2017-08-16 Interpace Diagnostics, Llc miARN como biomarcadores para distinguir entre neoplasias de tiroides benignas y malignas
EP2689033B1 (en) * 2011-03-22 2017-02-01 Cornell University Distinguishing benign and malignant indeterminate thyroid lesions
EP2505664B1 (en) * 2011-03-30 2014-12-03 Universität Leipzig Method and means for distinguishing malignant from benign tumor samples, in particular in routine air dried fine needle aspiration biopsy (FNAB)
US20130142728A1 (en) * 2011-10-27 2013-06-06 Asuragen, Inc. Mirnas as diagnostic biomarkers to distinguish benign from malignant thyroid tumors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4303323A1 (en) 2022-07-05 2024-01-10 Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Oddzial w Gliwicach A method differentiating benign and malignant tyroid nodules

Also Published As

Publication number Publication date
WO2015071876A3 (en) 2015-08-27
WO2015071876A2 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
PL406033A1 (pl) Sposób diagnozowania raka brodawkowatego tarczycy, zastosowanie markera mikroRNA do diagnozowania nowotworu tarczycy, oceny stopnia zaawansowania choroby oraz oceny podatności pacjenta i/lub choroby na zaproponowane leczenie oraz zawierający takie markery zestaw diagnostyczny
PL405648A1 (pl) Sposób diagnozowania raka watrobowokomórkowego, zastosowanie markera mikroRNA do diagnozowania zmiany chorobowej w obrębie wątroby, oceny stopnia zaawansowania choroby oraz oceny podatności pacjenta i/lub choroby na zaproponowane leczenie oraz zawierający takie markery zestaw diagnostyczny
PH12018550037A1 (en) Quencher containing water-soluble polymer-conjugated nanomaterial and use thereof
CL2008001517A1 (es) Dispositivo para determinar el riesgo de progresion de melanoma que comprende oligonucleotidos de uno o mas marcadores de pronostico de melanoma (mpms) escogidos de un grupo de seleccion; procedimiento para determinar la prognosis de melanoma en un paciente; procedimiento para determinar la adecuacion de un paciente de melanoma para un ensayo de droga.
BR112014030750A2 (pt) Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar
MX382266B (es) Metodo para el diagnostico, pronostico y tratamiento de la metastasis de cancer de mama.
WO2013190075A3 (en) Specific biomarkers for hepatocellular carcinoma (hcc)
MX2020006151A (es) Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk).
MY182773A (en) Method for indicating a presence or non-presence of aggressive prostate cancer
PH12015501868A1 (en) Inhibitors of histone demethylases
BR112018069849A2 (pt) kit, dispositivo e método para a detecção de câncer pancreático precoce ou de lesão precursora do câncer pancreático
MX2020001156A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
WO2014057357A3 (en) Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf
MX360236B (es) Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.
BR112015012644A2 (pt) método para determinar a necessidade de um paciente com câncer, método de tratamento do câncer, composição farmacêutica, uso de um ácido nucleico ou anticorpo e kit;
BR112012018132A2 (pt) "marcadores de células - tronco tumorais e uso dos mesmos".
MX2017015210A (es) Composiciones y metodos para el cribado de tumores solidos.
ATE554389T1 (de) Apex als marker für lungenkrebs
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
EA201490946A1 (ru) Способ количественной оценки лечения рака
WO2016130572A3 (en) Methods of determining levels of exposure to radiation and uses thereof
WO2009083780A8 (en) Breast cancer expression profiling
MY187050A (en) Cancer cell-specific antibody, anticancer agent, and cancer testing method
BR112015029550A2 (pt) Anticorpo anti-vegf e composição farmacêutica para prevenção, diagnóstico ou tratamento de câncer ou doença relacionada à angiogênese contendo o mesmo
Jiang et al. Node-extranodal soft tissue stage based on extranodal metastasis is associated with poor prognosis of patients with gastric cancer